Bristol-Myers Squibb Co.

NYSE:BMY  
76.20
+0.24 (+0.32%)
4:49:33 PM EDT: $76.26 +0.06 (+0.08%)
Products

Bristol-Myers Squibb Co Says U.S. FDA Approves First Lag-3-Blocking Antibody Combination Opdualag (Nivolumab And Relatlimab-Rmbw) As Treatment For Patients With Unresectable Or Metastatic Melano

Published: 03/18/2022 22:40 GMT
Bristol-Myers Squibb Co. (BMY) - U.S. Food and Drug Administration Approves First Lag-3-blocking Antibody Combination, Opdualag™ (nivolumab and Relatlimab-rmbw), As Treatment for Patients With Unresectable Or Metastatic Melanoma.